This article was originally published in The Gray Sheet
Firm starts a 200-patient, 22-site clinical trial Dec. 4 evaluating the fifth-generation Multi-Link Penta coronary stent, which features enhanced retention and conformability. Guidant launched its fourth-generation Multi-Link Tetra on Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16)
You may also be interested in...
Guidant is looking to its Multi-Link Tetra fourth-generation coronary stent platform to recoup a recent loss in U.S. stent market share, following a drop-off in demand for its Tri-Star stent.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.